The Federal Trade Commission is suing the three largest prescription drug benefit managers (PBMs) for allegedly driving up ...

Prior authorization is a key tool for ensuring high-quality patient care, but it needs to be refined, Humana CEO Jim Rechtin ...

Benefits Pro: Employers Need To Stop Maximizing PBM Drug Plan Rebates, Says Mark Cuban Cuban, the founder of the Mark Cuban Cost Plus Drug mail-order pharmacy, said the main rebate funding ...

Gold carding eliminates prior authorization for top-performing labs and eases plan workflows while controlling spending and ...

At issue is a report released by the FTC in July called: “Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug ...

AIDS Healthcare Foundation (AHF) joins the many healthcare providers outraged over Express Scripts’ meritless lawsuit designed to deflect attention away from PBM abuses that harm patient care. It is ...

WASHINGTON (Reuters) – Pharmacy benefit manager Express Scripts has sued the U.S. Federal Trade Commission over the regulator ...

Opens in a new tab or window Physicians frequently cite prior authorization requirements ... However, some groups did express concerns. A 2022 report from America's Health Insurance Plans (AHIP ...

Cigna division Express Scripts announced Friday that it's joining ... Biosimilars were nonexistent prior to the Affordable Care Act of 2010, which created a regulatory regime for the FDA to ...

Express Scripts is joining CVS Health in moving away from offering Humira as a standard prescription drug option for people with arthritis, Crohn's disease and other autoimmune disorders.

Now, Cigna’s Express Scripts is following suit in a move that could further chip away at Humira’s market share. Express Scripts, which is Cigna’s pharmacy benefit unit, is removing branded ...

Beginning in 2025, Express Scripts will favor biosimilars of Humira, including its own private-label version. Beginning in 2025, Express Scripts will remove Humira (adalimumab) from its commercial ...